HEALTHeUNIVERSE, Inc. (HLUN) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerHEALTHeUNIVERSE, Inc. (HLUN) trades at $0.0001. Healtheuniverse, Inc. is a biotechnology company focused on developing and commercializing biopharmaceutical, biomedical, nutraceutical, and cosmeceutical products. Their focus is on stem cell and regenerative medicine therapies using non-embryonic adult stem cells. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for HLUN: HLUN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HLUN against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
HLUN: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
HEALTHeUNIVERSE, Inc. (HLUN) Healthcare & Pipeline Overview
Healtheuniverse, Inc. is a biotechnology company specializing in the research, development, and commercialization of regenerative medicine therapies using non-embryonic adult stem cells. The company also offers consulting services in marketing, business organization, and capital raising, operating within the competitive healthcare and biotechnology sector.
What Is the Investment Thesis for HLUN?
Healtheuniverse, Inc. presents a high-risk, high-reward investment profile within the biotechnology sector. The company's focus on stem cell and regenerative medicine offers significant potential for growth, particularly given the increasing demand for advanced therapies in various surgical fields. However, the company's OTC listing and shell risk detection introduce substantial uncertainties. While the company boasts a high gross margin of 96.1% and a profit margin of 8.9%, its market capitalization of $0.00B indicates limited investor confidence. The success of Healtheuniverse hinges on its ability to successfully navigate the regulatory landscape, secure funding for ongoing research and development, and effectively commercialize its products. Investors should carefully consider the company's financial stability, competitive positioning, and the inherent risks associated with OTC-listed companies before making any investment decisions.
Based on FMP financials and quantitative analysis
HLUN Key Highlights
High Gross Margin: Healtheuniverse boasts a gross margin of 96.1%, indicating strong pricing power and efficient cost management in its product development.
- Profit Margin: The company has a profit margin of 8.9%, suggesting profitability in its operations, although further analysis is needed to assess sustainability.
- Stem Cell Focus: Healtheuniverse specializes in stem cell and regenerative medicine therapies, positioning it within a high-growth area of the biotechnology industry.
- Consulting Services: The company diversifies its revenue streams by offering consulting services in marketing, business organization, and capital raising.
- OTC Listing: Healtheuniverse trades on the OTC market, which presents both opportunities and risks due to lower regulatory oversight and liquidity.
Who Are HLUN's Competitors?
HLUN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| RLYB Rallybio Corporation | $16.75 | -1.30% | $88.9M | 825-pillar |
| ICCC ImmuCell Corporation | $9.91 | +0.05% | $89.7M | 775-pillar |
| ORMP Oramed Pharmaceuticals Inc. | $4.74 | -0.38% | $194M | 785-pillar |
| NAGE Niagen Bioscience Inc | $3.04 | -0.49% | $242M | 665-pillar |
| QTTB Q32 Bio Inc. | $10.93 | +1.96% | $325M | 685-pillar |
| NWPHF Newron Pharmaceuticals S.p.A. | $20.00 | 0.00% | $416M | 689-signal |
| CRMD CorMedix Inc. | $7.96 | -0.06% | $624M | 885-pillar |
| MDXG MiMedx Group, Inc. | $4.60 | -1.71% | $671M | 875-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are HLUN's Key Strengths?
Proprietary stem cell technology.
- Expertise in regenerative medicine therapies.
- Diversified revenue streams through consulting services.
- Focus on high-growth market segments.
What Are HLUN's Weaknesses?
Limited financial resources.
- OTC listing and associated risks.
- Dependence on regulatory approvals.
- Small market capitalization.
What Could Drive HLUN Stock Higher?
Clinical trial results for stem cell therapies could drive positive sentiment.
- Potential partnerships with larger pharmaceutical companies could provide funding and expertise.
- Regulatory approvals for new products could expand market access.
- Increasing demand for regenerative medicine therapies is a long-term growth driver.
- Expansion of consulting services could generate additional revenue streams.
What Are the Key Risks for HLUN?
Clinical trial failures could negatively impact the company's valuation.
- Regulatory delays or rejection of product approvals could hinder growth.
- Intense competition from larger biotechnology companies could erode market share.
- Limited financial resources and dependence on external funding.
- OTC listing and associated risks, including shell risk detection.
What Are the Growth Opportunities for HLUN?
- Expansion of Regenerative Medicine Therapies: Healtheuniverse has the opportunity to expand its range of regenerative medicine therapies for applications in plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. The market for regenerative medicine is projected to reach $150 billion by 2028, driven by increasing demand for minimally invasive procedures and personalized treatments. Success hinges on clinical trial outcomes and regulatory approvals.
- Strategic Partnerships and Collaborations: Healtheuniverse can pursue strategic partnerships and collaborations with hospitals, research institutions, and pharmaceutical companies to accelerate the development and commercialization of its products. Collaborations can provide access to funding, expertise, and distribution channels, enhancing the company's competitive position. This could involve joint ventures or licensing agreements to expand market reach.
- Geographic Expansion: Healtheuniverse can expand its geographic presence by targeting new markets in Asia, Europe, and Latin America. These regions offer significant growth potential due to increasing healthcare spending and aging populations. A phased approach, starting with key markets and strategic partnerships, would be essential for successful international expansion.
- Development of Cosmeceutical Products: Healtheuniverse can leverage its expertise in stem cell technology to develop innovative cosmeceutical products for anti-aging, skin rejuvenation, and hair growth. The global cosmeceuticals market is projected to reach $80 billion by 2027, driven by increasing consumer demand for effective and science-backed skincare solutions. This diversification could provide a stable revenue stream.
- Leveraging Consulting Services for Market Intelligence: Healtheuniverse's consulting services provide a unique opportunity to gather market intelligence and identify emerging trends in the healthcare and biotechnology sectors. This information can be used to refine the company's product development strategy and identify new growth opportunities. By understanding the needs of its consulting clients, Healtheuniverse can tailor its offerings to meet market demands.
What Are HLUN's Competitive Advantages?
- Proprietary stem cell technology.
- Expertise in regenerative medicine.
- Diversified revenue streams through consulting services.
- Focus on specific surgical applications.
What Does HLUN Do?
Healtheuniverse, Inc., founded in 2001 and headquartered in Covina, California, is a biotechnology development company focused on the research, development, and commercialization of a diverse range of products including biopharmaceuticals, biomedicals, nutraceuticals, and cosmeceuticals. The company's core focus lies in stem cell and regenerative medicine therapies, utilizing non-embryonic adult stem cells. These therapies are being developed for applications in various surgical fields, including plastic and reconstructive surgery, orthopedic surgery, vascular surgery, cardiac surgery, and wound care. Beyond its biopharmaceutical endeavors, Healtheuniverse, Inc. also provides consulting services to businesses, offering expertise in areas such as marketing, business organization, and capital raising. This dual approach allows the company to diversify its revenue streams while maintaining its commitment to innovation in the biotechnology sector. Healtheuniverse operates within the broader healthcare industry, targeting specific segments with its regenerative medicine solutions and consulting services.
What Products and Services Does HLUN Offer?
- Develops stem cell and regenerative medicine therapies.
- Focuses on non-embryonic adult stem cells.
- Targets applications in plastic and reconstructive surgery.
- Develops therapies for orthopedic surgery.
- Creates solutions for vascular and cardiac surgery.
- Offers products for wound care.
- Provides consulting services in marketing.
- Offers consulting in business organization and capital raising.
How Does HLUN Make Money?
- Develops and commercializes biopharmaceutical products.
- Generates revenue through the sale of biomedical products.
- Offers nutraceutical and cosmeceutical products.
- Provides consulting services to businesses.
What Industry Does HLUN Operate In?
Healtheuniverse, Inc. operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation, stringent regulatory requirements, and significant investment in research and development. Healtheuniverse's focus on stem cell and regenerative medicine aligns with key industry trends, but it faces competition from larger, more established players with greater financial resources and broader product portfolios. The company's success will depend on its ability to differentiate its products, secure regulatory approvals, and establish strategic partnerships.
Who Are HLUN's Key Customers?
- Hospitals and surgical centers.
- Patients seeking regenerative medicine therapies.
- Businesses seeking marketing and organizational consulting.
- Investors interested in biotechnology ventures.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 51 |
| 2026-08-26 | 51 |
| 2026-08-29 | 51 |
| 2026-09-01 | 51 |
| 2026-09-04 | 51 |
| 2026-09-07 | 51 |
| 2026-09-10 | 51 |
What changed?
The score has stayed at 51.
Over the same 18 days the stock moved +0.0%.
Company Profile
HEALTHeUNIVERSE, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Covina, US. The company is led by CEO Vipul Dev. HLUN has traded publicly since 2013.
HLUN Financials
Bull Case vs Bear Case
Bull Case
- Proprietary stem cell technology.
- Expertise in regenerative medicine therapies.
- Diversified revenue streams through consulting services.
- Focus on high-growth market segments.
Bear Case
- Limited financial resources.
- OTC listing and associated risks.
- Dependence on regulatory approvals.
- Small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
HLUN Latest News
No recent news available for HLUN.
HLUN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for HLUN.
Price Targets
Wall Street price target analysis for HLUN.
HLUN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for HLUN; grades run from A+ (80-100) to F (below 30).
Leadership: Vipul Dev
CEO
Vipul Dev serves as the CEO of Healtheuniverse, Inc. His background includes experience in business development, marketing, and finance, with a focus on emerging growth companies. He has a track record of assisting companies in raising capital and expanding their market presence. Vipul Dev's expertise lies in identifying and capitalizing on opportunities in the biotechnology and healthcare sectors. He has a strong understanding of the regulatory landscape and the challenges associated with commercializing new therapies.
Track Record: Under Vipul Dev's leadership, Healtheuniverse, Inc. has focused on developing its stem cell and regenerative medicine therapies. Key milestones include advancing research programs and securing partnerships to expand the company's reach. He has also overseen the company's consulting services, contributing to revenue diversification. His strategic decisions have aimed to position Healtheuniverse for long-term growth in the biotechnology sector.
HLUN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Healtheuniverse, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other companies face less stringent regulatory oversight, which can increase investment risk. This tier is often populated by shell companies, companies with distressed financials, or those that choose not to comply with higher reporting standards.
- OTC Tier: OTC Other
- Limited Financial Disclosure: The lack of comprehensive financial reporting increases the difficulty of assessing the company's true financial health and performance.
- Shell Risk: The detection of shell risk indicates a potential for fraudulent activity or lack of legitimate business operations.
- Liquidity Risk: Low trading volumes and wide bid-ask spreads can make it difficult to buy or sell shares at desired prices.
- Regulatory Scrutiny: OTC-listed companies are subject to less regulatory oversight, increasing the risk of non-compliance and potential legal issues.
- Price Volatility: The OTC market is prone to higher price volatility due to limited liquidity and speculative trading.
- Verify the company's legal standing and registration.
- Investigate the background and experience of the management team.
- Obtain and review any available financial statements and disclosures.
- Assess the company's business model and competitive positioning.
- Evaluate the company's intellectual property and patent portfolio.
- Check for any pending litigation or regulatory actions.
- Consult with a qualified financial advisor before investing.
- Focus on stem cell and regenerative medicine therapies.
- Consulting services to businesses.
- CEO with experience in business development and marketing.
- Development of products for plastic and reconstructive surgery.
- Headquartered in Covina, California.
What Investors Ask About HEALTHeUNIVERSE, Inc. (HLUN) — Healthcare
Is HLUN a good stock?
Stock Expert AI does not rate HLUN buy, sell or hold. HEALTHeUNIVERSE, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What do analysts say about HLUN stock?
Currently, there is no readily available analyst coverage for Healtheuniverse, Inc. (HLUN) due to its listing on the OTC market and its small market capitalization.
What are the key factors to evaluate for HLUN?
Evaluate HLUN on fundamentals, analyst consensus, and risk factors. This could involve joint ventures or licensing agreements to expand market reach. Not financial advice.
How frequently does HLUN data refresh on this page?
HLUN's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven HLUN's recent stock price performance?
HEALTHeUNIVERSE, Inc. (HLUN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary stem cell technology. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HLUN overvalued or undervalued right now?
HEALTHeUNIVERSE, Inc. (HLUN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of HLUN?
Yes, most major brokerages offer fractional shares of HEALTHeUNIVERSE, Inc. (HLUN) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track HLUN's earnings and financial reports?
HEALTHeUNIVERSE, Inc. (HLUN) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for HLUN earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing.
- Shell risk detected, indicating potential for fraudulent activity.
- Financial data may not be comprehensive or reliable.